ArticleEBioMedicine2025
Prophylactic protection from lethal henipavirus disease mediated by Nipah-derived defective interfering particles is influenced by challenge virus strain and viral species.
Article in EBioMedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHenipaviruses, including Nipah and Hendra viruses, are zoonotic pathogens that can cause severe respiratory and neurological diseases with high mortality rates in humans. Due to the severity of the disease, the high pandemic potential of these viruses, and the lack of approved treatments, the development of safe and effective medical countermeasures against henipaviruses is a critical priority.
methodsHere, we evaluate treatment efficacy of defective interfering particles (DIPs)-naturally occurring virus-like particles that lack substantial portions of the viral genome-against henipaviruses in the Syrian hamster model of disease.
findingsProphylactic DIP treatment markedly reduced clinical signs and lethality in Syrian hamsters. Single or repeated pre-exposure regimens, starting up to 3 days before challenge, provided protection, while post-exposure treatment was ineffective. DIPs derived from NiV strain Malaysia were most effective against NiV Malaysia but also provided strong protection against the closely related NiV Bangladesh with certain regimens. However, these DIPs offered minimal or no protection against lethality from the more distantly related Hendra virus.
interpretationOur data indicate efficacy of DIPs as a pre-exposure prophylactic for henipavirus infection and support a direct mechanism of viral inhibition.
fundingThis work was partially supported by the DARPAINTERfering and Co-Evolving Prevention and Therapy (INTERCEPT) program (DARPA-BAA-16-35), CDC Emerging Infectious Disease Research Core Funds, an appointment to the Research Participation Program at the Centers for Disease Control and Prevention (CDC) administered by the Oak Ridge Institute for Science and Education through an interagency agreement between the U.S. Department of Energy and CDC (K.A.D., S.E.R.), and by NIAID1R01AI151006 (T.E.S).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.